The estimated Net Worth of Capital Partners Iii Gp, L.... is at least $17.5 Million dollars as of 13 January 2020. Capital L owns over 1,250,000 units of Osmotica Pharmaceuticals Plc stock worth over $17,461,259 and over the last 5 years Capital sold OSMT stock worth over $0.
Sign up
Capital L OSMT stock SEC Form 4 insiders trading
Capital has made over 1 trades of the Osmotica Pharmaceuticals Plc stock since 2020, according to the Form 4 filled with the SEC. Most recently Capital bought 1,250,000 units of OSMT stock worth $6,250,000 on 13 January 2020.
The largest trade Capital's ever made was buying 1,250,000 units of Osmotica Pharmaceuticals Plc stock on 13 January 2020 worth over $6,250,000. On average, Capital trades about 1,250,000 units every 0 days since 2020. As of 13 January 2020 Capital still owns at least 15,730,864 units of Osmotica Pharmaceuticals Plc stock.
You can see the complete history of Capital L stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Insiders trading at Osmotica Pharmaceuticals Plc
Over the last 6 years, insiders at Osmotica Pharmaceuticals Plc have traded over $0 worth of Osmotica Pharmaceuticals Plc stock and bought 6,343,800 units worth $31,350,366 . The most active insiders traders include David F Burgstahler, Sriram Venkataraman und Ltd Orbit Co Invest A 1 Llc.... On average, Osmotica Pharmaceuticals Plc executives and independent directors trade stock every 117 days with the average trade being worth of $1,173,603. The most recent stock trade was executed by James Schaub on 16 December 2021, trading 93,800 units of OSMT stock currently worth $100,366.
What does Osmotica Pharmaceuticals Plc do?
Osmotica Pharmaceuticals plc is a fully integrated biopharmaceutical company focused on the development and commercialization of specialty products that target markets with underserved patient populations. The company has a diverse portfolio consisting of promoted and non-promoted products, several of which incorporate Osmotica’s proprietary Osmodex® drug delivery system. RVL Pharmaceuticals, Inc. is the Company’s ophthalmic subsidiary supporting Upneeq®. Vertical Pharmaceuticals, LLC represents the Company’s diversified branded portfolio and Trigen Laboratories, LLC represents the Company’s non-promoted products, including complex generic formulations. Osmotica has operations in the United States, Argentina, and Hungary.
What does Osmotica Pharmaceuticals Plc's logo look like?
Complete history of Capital L stock trades at Osmotica Pharmaceuticals Plc
Osmotica Pharmaceuticals Plc executives and stock owners
Osmotica Pharmaceuticals Plc executives and other stock owners filed with the SEC include:
-
Brian Markison,
Chairman of the Board, Chief Executive Officer -
Christopher Klein,
General Counsel, Secretary -
Tina deVries,
Executive Vice President - Research & Development -
James Schaub,
Chief Operating Officer, Executive Vice President -
Brian A. Markison,
Chairman, Pres & CEO -
Christopher A. Klein,
Gen. Counsel & Sec. -
James D. Schaub,
Exec. VP & COO -
Dr. Tina Marie deVries,
Exec. VP of R&D -
Andrew Einhorn,
Chief Financial Officer -
Fred Weiss,
Independent Director -
Gregory Cowan,
Independent Director -
David Burgstahler,
Director -
Sriram Venkataraman,
Director -
Juan Vergez,
Director -
Michael DeBiasi,
Independent Director -
Lisa Wilson,
IR Contact Officer -
Joachim Benes,
Director -
Andrew J. Einhorn CPA,
Chief Financial Officer -
Jarret Miller,
Exec. VP of HR -
Sergio Alegre,
VP of Global Compliance -
Capital Partners Iii Gp, L....,
-
Ltd Orbit Co Invest A 1 Llc...,
-
Foundation Harsaul,
10% owner -
Capital Partners Iii Gp, L....,